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BACKGROUND: The key mediator of new vessel formation in cancer and other diseases is VEGF-A. VEGF-A exists as alternatively
spliced isoforms - the pro-angiogenic VEGFxxx family generated by exon 8 proximal splicing, and a sister family, termed VEGFxxxb,
exemplified by VEGF165b, generated by distal splicing of exon 8. However, it is unknown whether this anti-angiogenic property of
VEGF165b is a general property of the VEGFxxxb family of isoforms.
METHODS: The mRNA and protein expression of VEGF121b was studied in human tissue. The effect of VEGF121b was analysed by
saturation binding to VEGF receptors, endothelial migration, apoptosis, xenograft tumour growth, pre-retinal neovascularisation and
imaging of biodistribution in tumour-bearing mice with radioactive VEGF121b.
RESULTS: The existence of VEGF121b was confirmed in normal human tissues. VEGF121b binds both VEGF receptors with similar affinity
as other VEGF isoforms, but inhibits endothelial cell migration and is cytoprotective to endothelial cells through VEGFR-2 activation.
Administration of VEGF121b normalised retinal vasculature by reducing both angiogenesis and ischaemia. VEGF121b reduced the
growth of xenografted human colon tumours in association with reduced microvascular density, and an intravenous bolus of
VEGF121b is taken up into colon tumour xenografts.
CONCLUSION: Here we identify a second member of the family, VEGF121b, with similar properties to those of VEGF165b, and
underline the importance of the six amino acids of exon 8b in the anti-angiogenic activity of the VEGFxxxb isoforms.
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The advent of anti-neovascular therapies in cancer and eye disease
has prompted a burgeoning interest in the mechanisms behind the
initiation, development and refinement of new vessel formation.
The growth of new vessels from those already established is termed
angiogenesis and although a complex process, involving over 50
growth factors, cytokines, receptors and enzymes, is dominated, in
most situations, by the 38kDa cysteine-knot protein vascular
endothelial growth factor (VEGF). Following the initial identifica-
tion of VEGF (Senger et al, 1983) many splice isoforms were
subsequently identified, eventually forming a family of mature
peptides – the VEGFxxx family (see Figure 1) (Houck et al, 1991).
The individual family members have different expression patterns
(e.g., VEGF183 expression is mostly restricted to the eye (Jingjing
et al, 1999), VEGF145 in the reproductive system (Charnock-Jones
et al, 1993)); unique characteristics with respect to heparin and
receptor-binding properties (resulting from inclusion/exclusion of
particular exon segments) and are named by amino acid size.
Despite this heterogeneity they are all considered pro-angiogenic,
pro-permeability vasodilators. The evidence for these properties
for individual splice isoform recombinant proteins in vivo,
however, varies from conclusive (VEGF165) (Leung et al, 1989),
through mixed (VEGF121) (Keyt et al, 1996; Zhang et al, 2000) and
scanty (VEGF145) (Poltorak et al, 1997) to absent (VEGF206).
In addition, it has now become evident that even the presence of
six splice isoforms is an over-simplification. The pro-angiogenic
potential of conventional VEGF isoforms is thought to result from
the C-terminus (Keyt et al, 1996), more specifically the six amino
acids of exon 8a – CDKPRR (Cebe Suarez et al, 2006; Cebe-Suarez
et al, 2008). A sister family of splice isoforms has now been
identified (see Figure 1) in which the pro-angiogenic domain
(exon 8a) is replaced by the six amino acids coded for by exon 8b –
SLTRKD. These exon 8b isoforms (VEGFxxxb) are exemplified by
the only isoform so far extensively investigated, VEGF165b.
VEGF165b has radically different properties to that of the widely
studied VEGF165. We, and others have shown that VEGF165b is not
pro-angiogenic in vivo (Woolard et al, 2004) and specifically and
actively inhibits VEGF165-mediated endothelial cell proliferation
and migration in vitro (Bates et al, 2002; Rennel et al, 2008a,b),
vasodilatation ex vivo (Bates et al, 2002) and in vivo angiogenesis
assays such as rabbit corneal eye pocket, chicken chorioallantoic
membrane, mesenteric and Matrigel implants (Woolard et al, 2004;
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sCebe Suarez et al, 2006; Kawamura et al, 2008). Furthermore,
VEGF165b not only inhibits physiological angiogenesis in deve-
loping mammary tissue in transgenic animals over-expressing
VEGF165b (Qiu et al, 2008) but also pathological angiogenesis in
models of the proliferative ocular lesions of diabetes (retinopathy
of pre-maturity) (Konopatskaya et al, 2006) and age-related
macular degeneration (laser-induced choroidal neovascularisation,
Hua et al, unpublished) and in six different tumour models in vivo
(Woolard et al, 2004; Varey et al, 2008; Rennel et al, 2008a,b).
The above anti-angiogenic properties occur when delivered as
VEGF165b-transfected cells (Woolard et al, 2004; Varey et al, 2008;
Rennel et al, 2008a), VEGF165b-adenoviral constructs (Woolard
et al, 2004) or recombinant human protein (Konopatskaya et al,
2006; Rennel et al, 2008b).
Although a significant amount of evidence on the expression
and function of the VEGF165b isoform has already been published,
there is very little evidence on other VEGFxxxb family members,
and their existence and activity is still uncertain. This study,
therefore, investigates the properties of a second member of the
VEGFxxxb family – the peptide VEGF121b, addressing the hypo-
thesis that VEGF121b will also show anti-angiogenic properties. We
present descriptive expression data and functional data on cell
migration, receptor binding and in vivo tumour and ocular
angiogenesis in vivo.
MATERIALS AND METHODS
Tissue samples
Paired colon samples were from partial colon resection for
carcinoma. Samples were obtained by taking biopsies of the fresh
specimen from a non-necrotic central portion of the tumour and
from a peripheral part of the macroscopically normal colon
(n¼15). The mean patient age was 71.5 (58–80) years, with 62%
males and Duke’s staging as follows: 6.7% A, 46.7% B and 46.7% C.
Informed consent for obtaining the tissue was gained in
compliance with local ethics committee approval.
PCR on cDNA from human total RNA
Total RNA was extracted from human tissue using TRIZOL
(Invitrogen, Carlsbad, CA, USA) (Chomczynski, 1993) and treated
with DNase (Promega, Madison, WI, USA). Complementary DNA
was made using oligo dT primers or 30UTR primer (GCTCTA
GAAGCAGGTGAGAGTAAGCG) as described earlier (Bates et al,
2002). PCR was used to identify presence of VEGF121b, VEGF165
and VEGF165b using specific primers; VEGF165/VEGF165b exon 7
GGCAGCTTGAGTTAAACGAACG, 30UTR ATGGATCCGTATCAG
TCTTTCCTGG, VEGF121b exon 5/8b GAAAAATCTCTCACCAGG
Distal splice
site
VEGFxxxb
VEGFxxx
ACTTGCAG gttgg……tcag ATGTGACAAGCCGAGGCGGTGAgccgggcaggaggaaggagcctccctcagggtttcgggaaccag ATCTCTCACCAGGAAAGACTGA tacagaacgatcgatacc
Exon 5/6/7 Exon 8a Exon 8b
Proximal
splice site
SLTRKD
CDKPRR
Ex1 Ex 8a-b   Ex 4 Ex 7a 6b 7b
VEGF-R1
binding
VEGF-R2
binding
Heparin & Nrp
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VEGF-A structure
VEGF206
VEGF189
VEGF165
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VEGF145b
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Alternative splicing of VEGF-A
Two families of VEGF-A proteins
Ex 5 Ex 6a Ex 3 Ex 2
Figure 1 Alternative splicing of VEGF-A generating VEGFxxx and VEGFxxxb isoforms. (A) VEGF-A contains eight exons with receptor binding found in
exons 3 and 4, heparin and neuropilin binding in exons 6 and 7 and 8a. (B) Alternative splicing of the C-terminal end using proximal splice site generating
VEGFxxx isoforms or distal splice site generating VEGFxxxb isoforms. This splicing leads to an alterative last six amino acids (CDKPRR or SLTRKD). (C) The
C-terminal splicing leads to the possibility of two sister families of VEGF-A isoforms; VEGFxxx and VEGFxxxb, differing only in the C-terminal.
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sAAA, 30UTR II CTGGATTAAGGACTGTTCTG, VEGF121 exon 5/8a
GAAAAATGTGACAAGCCGAG 30UTR II CTGGATTAAGGACTGT
TCTG, GAPDH forward TGATGACATCAAGAAGGTGGTGAAG,
reverse TCCTTGGAGGCCATGTGGGCCAT and PCR products
were separated and visualised using 4% agarose/ethidium
bromide gel. Putative VEGF121b PCR products were purified using
QIAquick gel extraction (Qiagen, Crawley, UK) and inserted into
pGEM vector and confirmed by sequencing of plasmid.
Production of recombinant protein
Recombinant human VEGF121b (VEGF121b) and VEGF165b were
produced in Chinese hamster ovary cells as glycosylated dimers by
Cancer Research Technologies (London, UK) as described earlier
(Rennel et al, 2008b). VEGF165 and VEGF121 were from R&D
Systems, Minneapolis, MN, USA.
In vitro assays with human umbilical vein endothelial cells
Human umbilical vein endothelial cells (HUVEC) were extracted
from umbilical cords from caesarean sections (St Michael’s
Hospital, Bristol, UK). HUVEC migration was performed as
described earlier (Rennel et al, 2008b). Briefly, HUVECs were
serum starved for 6h and 100000 serum-starved cells were plated
into collagen-coated 8mm inserts (Millipore, Billerica, MA, USA)
placed in 24-well plates with 500ml of chemoattractant in M200
medium with 0.1% v/v FCS and 0.2% w/v BSA and incubated
overnight at 371C to allow for migration. Migrating cells were
stained in Mayer’s haematoxylin. Migrating cells were counted (10
random fields per insert) and expressed as percentage of migrating
cells in relation to the total number of seeded cells. Experiments
were performed in triplicates. A peptide (Ac-SLTRKD) was
generated and increasing concentrations (1nM–100mM) peptide
was combined with or without 1nM VEGF165 to analyse impact on
HUVEC migration.
Cell cytotoxicity was performed using a lactate dehydrogenase
assay (Promega); 13000 cells were seeded in cell culture 96-well
plates in triplicates or quadruplicates in 100ml of full growth media
(FGM) for 24h. Recombinant VEGF protein was added in 100ml
media with 0.1% FCS for 48h. Conditioned media and lysed cells
were spun at 250g for 15min at 41C followed by addition of kit
components, incubated for 30min and read at 490nm. Receptor
and kinase inhibitors were added at indicated concentrations with
or without 1.4nM VEGF121b.
For direct counting, HUVECs were seeded in 24-well plates in
triplicates in FGM 24h followed by 48h exposure to 1.4nM growth
factors or FGM. Cells were trypsinised and counted using a
haemocytometer.
In vivo tumour model
LS174t human colon carcinoma cell lines (ECACC, Salisbury, UK)
(Yuan et al, 1996; Lee et al, 2000) were grown in Minimum
Essential Eagle’s Medium supplemented with 10% v/v FCS,
2m ML -glutamine and 1% non-essential amino acids (all from
Sigma Aldrich, Gillingham, UK). Cells were transfected with
1mg/well of pcDNA3 empty vector or pcDNA3-VEGF121b, using
lipofectamine plus (Invitrogen) as per manufacturer’s instructions
and selected using 500mgml
 1 geneticin (Sigma Aldrich). Condi-
tioned media and cell lysate were analysed by western blotting to
confirm expression levels of VEGF isoforms. Two million cells
were injected subcutaneously into the lumbar region of nude mice
(six per group). Xenotransplanted tumours were measured by
calliper every 2–3 days and tumour volume was calculated
according to (length width [lengthþwidth]/2). Mice were
culled by cervical dislocation and tumours were removed when
the first tumour reached 16mm in any direction all mice were
killed in that group. Injections, measurements and analysis were all
carried out with the investigators blinded to group.
Tumour vessel density was counted in 10 random fields in
haematoxylin and eosin stained 6mm sections frozen sections from
tumours. Vessel presence was confirmed by staining by blocking in
5 %v / vg o a tI gf o r3 0 m i n ,2 0 mgml
 1 biotinylated isolectin
B4 (L-2140 Sigma-Aldrich) or 1mgml
 1 Flk-1 (sc-6251, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) overnight, 2mgml
 1 anti-mouse
biotin antibody (Vector Laboratories, Burlingame, CA, USA) for 1h
followed by avidin biotinylated enzyme complex (Vector Laboratories)
for 30min followed by DAB substrate (Vector Laboratories). Sections
were examined using a Nikon Eclipse E400 microscope and photos
were captured using Nikon Eclipse Net software. To visualise
apoptosis, tumour sections were stained with cleaved caspase 3
antibody (1:400 dilution, CatNo9661 Cell Signaling Technology,
Danvers, MA, USA) and positive staining areas were circled and
compared to total tumour area using Image J software.
Cell proliferation by flow cytometry analysis and direct
counting
Trypsinised LS174t cells were fixed in 70% ethanol for 30min at
41C followed by 100mgml
 1 ribonuclease (Sigma Aldrich) for
5min. Propidium iodine (PI, 50mgml
 1) was added to the cells
and analysed by flow cytometer.
For healthy, apoptotic and necrotic cell determination a
PI-annexin V-FITC kit was used (Bender MedSystems, Vienna,
Austria). Cell culture media was centrifuged at 1500r.p.m. to
collect non-adherent cells, added to trypsined cells and diluted in
binding buffer to approximately 300000 cells/ml. Cells were
stained with 25ml annexin V-FITC for 10min, washed, stained
with 20mgml
 1 PI and analysed by flow cytometer.
For direct counting, 135000 LS174t cells/24 well was seeded out
in triplicates in media supplemented with 0.1% FCS in the
presence or absence of 1nM VEGF121b. Cells were trypsined and
counted using a haemocytometer after 24 and 48h.
In vivo imaging of
125I-VEGF165b biodistribution
Nude mice were injected with LS174t tumours on the right hindleg.
125I-VEGF121b was generated using Iodogen tubes (Pierce Biotech-
nology, Cramlington, UK) and purified with NAP-10 columns
(GE Healthcare, Chalfont St Giles, UK). Analysis by thin layer
chromatography showed 495% purity (
125I-VEGF121b/total
125I).
Approximalty 3.2MBq (70mg protein) was injected into the tail
vein when tumours were 410mm in diameter. Anaesthesia
was maintained by 2% halothane during X-ray and scanning
(NanoSPECT/CT, Bioscan, Washington, DC, USA), after 40, 70,
120, 240 or 1440min. For biodistribution studies, 0.10MBq (3mg)
125I-VEGF121b was injected into the tail vein and mice were culled
at 120 or 240min. Organs and tissues of interest were excised and
assessed using a gamma counter (LKB Wallac 1282 Compugamma
CS, Wallac, Perkin Elmer, MA, USA). Uptake was expressed as %
injected dose/g tissue.
In vitro saturation binding of
125I-VEGFxxxbt o
Fc-VEGFR-1
One mgml
 1 human VEGFR-1-Fc chimaera or VEGFR-2-Fc (R&D
Systems) was bound to Immulon II HB Flat 96-well plates (Thermo
Labsystems, Basingstoke, UK) overnight followed by blocking
with 3% w/v BSA for 2h and binding of
125I-rhVEGF121bo r
125I-rhVEGF165b for 4h in 1% w/v BSA in triplicates. Plates were
washed three times with PBSþ0.05% v/v Tween in between
each step. To detach the complex 10% w/v SDS was added and
counted in a gamma counter. Data were calculated as c.p.m. and
expressed as % binding compared with maximum binding
concentration.
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Tissue lysates from transfected cells or human colon tissue were
extracted using RIPA buffer (50mM Tris, 150mM NaCl, 1% v/v
NP-40, 0.25% w/v Na-deoxycholate, 1mM EDTA, 1mM phenyl-
methylsulfonyl fluoride, 1mgml
 1 of each of aprotinin, pepstatin
and leupeptin) and homogenised using a polytron and spun at
12000r.p.m. for 10min at 41C. Lysates were separated on 15%
SDS–PAGE, transferred to polyvinylidene fluoride membranes,
blocked in 10% w/v dry milk, incubated with a mouse monoclonal
anti-human VEGFxxxb antibody (2mgml
 1, R&D Systems) for 1h
followed by horse radish peroxidase conjugated anti-mouse
antibody (1/5000, Pierce Biotechnology) for 1h. Membranes were
developed using supersensitive West Femto Maximum Sensitive
Substrate (Pierce Biotechnology). Densitometry analysis of western
blots was performed using Image J. VEGF121b is detected by
immunoblotting using anti-VEGF antibodies (A-20 Santa Cruz or
AF-293 R&D Systems) and the commercial VEGFxxxb antibody
(A56/1, R&D Systems, cat no. MAB3045). Commercial ELISA for
VEGF165b (R&D Systems) and panVEGF (Duoset R&D Systems)
can pick up VEGF121b but panVEGF ELISA underestimates the
VEGF121b levels (and VEGF165b) by approximately 40% (Varey
et al, 2008).
Oxygen-induced retinopathy mouse model
The oxygen-induced retinopathy (OIR) model was performed as
described earlier (Smith et al, 1994; Konopatskaya et al, 2006) with
minor modifications. Neonatal C57/Bl6 mice and nursing CD1
dams were exposed to 75% oxygen between P7 and P12. Return to
room air induced hypoxia in the ischaemic areas. On P13, mice
received either VEGF121b (1 or 10ng) or Hank’s buffered solution
in 1ml intraocular injections using a Nanofil syringe fitted with a
35 gauge needle (WPI, Sarasota, FL, USA) into the left eye under
isoflurane anaesthesia. On P17, both eyes were dissected, fixed in
4% paraformaldehyde for 4h at 41C and retinas were dissected.
Retinas were permeabilised in PBS containing 0.5% Triton X-100
and 1% bovine serum albumin, stained with 20mgml
 1 biotiny-
lated isolectin B4 (Sigma Aldrich) in PBS pH 6.8, 1% Triton-X100,
0.1mM CaCl2, 0.1mM MgCl2, followed by 20mgml
 1 ALEXA
488-streptavidin (Molecular Probes, Eugene, OR, USA) and flat
mounted in Vectashield (Vector Laboratories). Quantification
of neovascular and ischaemic areas were performed in a blinded
fashion using Photoshop CS3 along with Image J and expressed
as percentage of total retinal area (¼normalþischaemicþ
neovascular).
Statistical analysis
Statistical analysis was performed using GraphPad Prism software
(version 4.0cx). Data are given as means±s.e.m. or means±95 %
confidence interval when stated. One-way ANOVA was used to
compare migration, cytoprotection, tumour growth and retinal
vascularisation. T-test was used to compare tumour growth,
apoptosis and microvascular density and paired t-test used for
retinal areas.
RESULTS
Expression of VEGF121b in human colon tissue and its
reduction in colon carcinoma
Earlier, we reported a shift in expression of VEGFxxxb isoforms in
human malignant melanoma (Pritchard-Jones et al, 2007), prostate
(Woolard et al, 2004; Rennel et al, 2008a) and colon carcinoma
(Varey et al, 2008) leading to less anti-angiogenic VEGFxxxb splice
isoforms in cancer tissue. The ELISA used to quantify the levels of
VEGFxxxb isoforms does not distinguish between the individual
members of the VEGFxxxb isoform family. Earlier RT–PCR used to
detect VEGFxxxb isoforms (using exon 7 and 30UTR primers) did
not detect VEGF121b (see Figure 2A) as the forward primer was in
exon 7 (spliced out in VEGF121b and VEGF121). To identify
VEGF121b, mRNA primers were used that spanned the exon 5/exon
8b boundary. These primers detected VEGF121b but not VEGF165b
or VEGF165 (see Figure 2B). VEGF121b was detected in normal
tissue such as aorta, spleen, placenta and some normal and tumour
colon tissue (see Figure 2B), which also expressed VEGF165 and
VEGF165b (see Figure 2A) and retina and vitreous (Figure 2C).
Presence of VEGF121b was confirmed by sequencing of PCR
products.
Measurement of VEGF levels in an earlier study on human colon
carcinoma showed that the angiogenic VEGF isoforms were
upregulated compared with matched colon tissue whereas the
levels of anti-angiogenic VEGFxxxb isoforms remained unchanged.
Western blot on that tissue showed two bands consistent with
expression of VEGF121b and VEGF165b (Varey et al, 2008).
Quantification of the western blot analysis of paired human colon
tissues from tumour and adjacent normal colon tissue indicates a
downregulation of VEGF121b in tumour tissue compared to
VEGF165b (see Figure 2D, Po0.01 paired t-test, n¼14 pairs).
VEGF121b is secreted, inhibits migration and reduces
apoptosis in endothelial cells
To determine whether VEGF121b can be secreted by colon cells,
VEGF121b recombinant cDNA was transfected into colon carci-
noma cells. Western blotting of the lysate and the media showed
that VEGF121b was found pre-dominantly in the media, indicating
that it is freely secreted (see Figure 3A), in contrast to cells that were
not transfected with the VEGF121b plasmid, in which no VEGF121b
was seen in the media or the lysate. VEGF121b binding to VEGFR-1
was analysed by incubating increasing concentrations of radio-
labelled VEGF121b with immobilised VEGFR-1 (see Figure 3B).
The saturation-binding kinetics of VEGF121b (see Figure 3B,
log10EC50¼ 9.9±0.04) was similar to that for VEGF165b measured
at the same time (EC50¼ 9.65±0.04, Figure 3C).
We have shown earlier that VEGF165b conditioned media
(Bates et al, 2002; Rennel et al, 2008a) or recombinant human
VEGF165b (Woolard et al, 2004; Rennel et al, 2008b) inhibits
VEGF165-induced migration of endothelial cells. Migration of
HUVEC was inhibited by the addition of VEGF121b either when
stimulated with VEGF165 (see Figure 3D, VEGF165 vs any treat-
ment Po0.05) or VEGF121 (see Figure 3E, VEGF121 vs any
treatment Po0.05). The level of inhibition was similar to that
observed with VEGF165b (see Figure 3D) and no additional
significant reduction in migration was observed with the
combination of VEGF121b and VEGF165b (see Figure 3D). Addition
of up to 100mM peptide of the last six amino acids had no effect on
VEGF165-induced HUVEC migration (data not shown) indicating
that the 3D structure and or the full length of the VEGFxxxb protein
is needed for inhibition.
VEGF165 is known to protect endothelial cells from apoptosis
and incubation of HUVECs with recombinant VEGF121b was
equally cytoprotective (see Figure 3F, no addition vs any treatment
Po0.01). This resulted in a small increase in cell number induced
by treatment with VEGF121b (see Figure 3G). To determine the
mechanism of this cytoprotective effect of VEGF121b, HUVECs
were treated with inhibitors of receptor tyrosine kinases and
signalling kinases (see Figure 3H). Inhibition of VEGFR-1 and
VEGFR-2 by 100nM PTK787 resulted in an inhibition of the
cytoprotective effect of VEGF121b, as did incubation with the
VEGFR-2-specific antagonist ZM323881 (10nM). The cytoprotec-
tive effect was blocked by inhibitors of PI3Kinase (LY294002) and
MEK1/2 (PD98059), but not by inhibitors of p38 MAPK (SB203580,
see Figure 3H).
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through a direct effect on endothelial cells
We have shown earlier that over-expression of VEGF165b reduces
tumour growth in five different tumour types (Woolard et al, 2004;
Varey et al, 2008; Rennel et al, 2008a), but VEGF165b does not
directly affect proliferation or apoptosis of LS174t cells (Varey
et al, 2008). To verify whether VEGF121b could inhibit tumour
growth as well, LS174t colon carcinoma tumour cells were
transfected with plasmid containing VEGF121b or cloning vector
alone (control). Expression levels were confirmed by immunoblot
on lysate and conditioned media showing that VEGF121b was
secreted and found in the media (see Figure 3A). Cells were
injected into the back of nude mice and tumour growth was
monitored over time. VEGF121b reduced tumour growth compared
with empty vector (290±66mm
3 vs 925±268mm
3 after 14 days,
Po0.05, unpaired t-test Welch correction, see Figure 4A).
VEGF121b tumours were smaller and excised tumours were less
haemorrhagic than those with empty vector (see Figure 4A
inserted images). Immunohistochemical staining was performed
to visualise blood vessel distribution (see Figure 4B for repre-
sentative VEGFR-2 staining). Analysis of the vessel density in
10 random fields in each tumour showed a decreased number of
vessels in VEGF121b tumours (control vs VEGF121b, 3.5±0.6 vs
1.7±0.1, Po0.05 unpaired t-test n¼6 tumours per treatment
10 fields analysed per tumour, Figure 4B). VEGFR-2 staining of
tumour sections showed expression of VEGFR-2 in the tumour
vessels and not in the general tumour mass (see Figure 4B inserted
images) indicating an effect of VEGF121b on the endothelium
rather than an anti-proliferative effect on the tumour cells. Earlier
analysis has shown absence of VEGFR-1 and VEGFR-2 expression
in LS174t cells (Rennel et al, 2008b). To determine whether
VEGF121b expression induced apoptosis in the tumour cells,
tumours were stained for cleaved caspase 3. There was no change
in caspase staining in control vs VEGF121b-expressing tumours
(see Figure 4C).
Transfected LS174t colon cells were analysed by flow cytometry
and VEGF121b had no effect on proliferation (see Figure 4D control
vs VEGF121b, S/G2-M 21±2.3 vs 27±4.4, P¼0.36 unpaired t-test).
In addition, addition of recombinant VEGF121b had no effect on
tumour cell number (see Figure 4F). These data indicate that
VEGF121b reduced tumour growth by reducing the tumour-driven
angiogenesis, rather than a direct effect on the tumour cells
themselves.
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Figure 2 VEGF121b is expressed in human tissue and the expression is reduced in human colon tumours. (A–C) PCR on cDNA from different human
tissues using primers to detect VEGF121b, VEGF165b and VEGF165. VEGF165 and VEGF165b are detected in colon cDNA both in tumour and adjacent control
colon (A). VEGF121b is detected in colon tissue, aorta, spleen and placenta using VEGF121b-specific primers (B). VEGF121, 165, 121b and 165b can be found in
the retina and to a lesser extent in the human vitreous (C). (D) Densitometry analysis of VEGF121b and VEGF165b protein expression in matched human
control colon samples and colon tumours analysed by western blot using a VEGFxxxb-specific antibody (n¼14 pairs, P¼0.0067 paired t-test).
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The results above indicate that VEGF121b could be a potential
therapeutic agent in angiogenic diseases, if the uptake into
neovascular tissues was sufficient. To determine how intravenously
(i.v.) injected recombinant VEGF121b is distributed in vivo,
125I-VEGF121b was injected i.v. into tumour-bearing mice and
imaged using high-resolution single photon emission computed
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Figure 4 VEGF121b reduces tumour growth in nude mice bearing colon carcinoma tumours by reducing tumour vessel ingrowth. (A) LS174t human
colon carcinoma cells were transfected with pcDNA3-VEGF121b or empty pcDNA3 plasmid and injected subcutaneously into nude mice and tumour
growth was monitored over time. Over-expression of VEGF121b resulted in a reduced tumour growth and contained less blood compared with control cells
(inserted images). Scale bar¼10mm. (B) Immunohistochemistry staining of tumour sections for VEGFR-2 visualise microvessels (inserted images).
Quantification of microvascular density showed significantly fewer blood vessels per unit area than control tumours. Each point represents the meano f
10 random analysed fields and six tumours per treatment were examined (*Po0.05 unpaired t-test). (C) Cleaved caspase 3 staining of tumour sections
(inserted images) showed no significant difference in apoptosis. (D, E) VEGF121b has no effect on LS174t colon carcinoma growth in vitro. Over-expression
of VEGF121b in LS174t colon carcinoma cells had no effect on cell proliferation analysed by FACS (D). Addition of 1nM VEGF121b had no effect of cell
number analysed by direct counting of cells over 48h (E).
Figure 3 VEGF121b inhibits migration of endothelial cells and inhibits serum starved induced cell death in endothelial cells through classical VEGFR-
induced pathways. (A) VEGF121b is found in the media on transfected cancer cells. (B–C) VEGF121b has similar saturation binding kinetics to VEGFR-1 as
VEGF165b. (D–E) VEGF121b inhibits VEGF165 (D) or VEGF121 (E) induced migration of HUVEC. Cells were allowed to migrate through 8 mm pore inserts
with increasing concentrations of VEGF121b (0–6 nM) or VEGF165b (0–2.5 nM) in the presence of 1 nM VEGF165 or 2.9 nM VEGF121. Data plotted as
percentage migration compared to total number of seeded cells (F) VEGF121b is cytoprotective to a similar degree as VEGF165 in HUVEC. Release of lactate
dehydrogenase as a measurement of cell viability was monitored after 48 h of serum starvation in the presence of increasing amounts of VEGF121b
(0–3.6 nM), 1 nM VEGF165 or full growth media (FGM) with serum and growth factors. (G) Similar cytoprotection of VEGF121b was observed in serum
starved HUVEC as cell number was not reduced by the same amount after 48 h of cell starvation. (H) VEGF121b cytoprotection is mediated via VEGFR-1
and -2, P13-K, MEK1/2. Inhibition of VEGFR1/2=200 nM PTK787, VEGFR-2=10 nM ZM323881, P13- K=15 mM LY294002, p38=10 mM SB203580 and MEK1/
2=15 mM PD98059. (One-way ANOVA, Dunnett’s post hoc test, 0 nM or control vs addition, *Po0.05, **Po0.01, ***Po0.001).
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stomography (NanoSPECT/CT). Radiolabelled VEGF121b was distri-
buted quickly through the mouse and images acquired at 40min
post injection (p.i.) showed accumulation in organs of meta-
bolism and secretion. Thereafter, the overall signal gradually
declined because of excretion/degradation of the radiolabelled
protein. Figure 5A shows whole body images at different time
p.i. Uptake of radioactivity can be seen in the tumour as well as
abdominal tissues such as stomach and kidney. Coronal and
sagittal sections also visualised uptake in the tumour at 2h p.i.
(see Figure 5E-F). Biodistribution of tissue and tumour indi-
cated that approximately 2.5% of the total
125I is found in the
tumour at 2h and stays at a similar level for up to 24h (see
Figure 5G). Intestine and liver showed high uptake with a
maximum at 4h. No obvious adverse haemodynamic effects were
seen in the animals.
VEGF121b rescues retinal vasculature by reducing
neovascularisation and ischaemia
We have shown earlier that the anti-angiogenic VEGF165b can
inhibit retinal neovascularisation in an OIR mouse model when
administered as a single intraocular injection (Konopatskaya
et al, 2006). In this model retinal vaso-obliteration occurs in the
central retina when pups are exposed to high oxygen (from P7 to
P12) and when returned to room air the relative hypoxia
induces neovascularisation with a peak reached at P17. Retinas
were flat mounted and stained with isolectin to visualise vessels
with neovascularisation occurring at the edge of the central
ischaemic area (see Figure 6A). Blind quantification of the
injected and uninjected contralateral retina, showed reduced
neovascularisation after 1 or 10ng VEGF121b (see Figure 6B-C,
40 min
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Figure 5 In vivo distribution of
125I-VEGF121b in tumour-bearing mice. Tumour-bearing mice received an intravenous injection of
125I-VEGF121b and 3D
imaged using NanoSPECT/CT. (A–D) Time course for biodistribution of
125I-VEGF121b after tail vein injection using transverse sections. (E) Coronal.
(F) Para-sagittal through the centre of the tumour. The tumour is circled and arrows indicate different organs. (G) Quantification uptake into different organs
and tissues over time. Data expressed as % in tissue relative to the total injected dose, per gram of tissue.
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suninjected control vs 1 or 10ng VEGF121b Po0.05 or control
injection vs 1 or 10ng VEGF121b Po0.05). Injection of 10ng
VEGF121b reduced the ischaemic area, and increased the area of
normal vasculature (see Figure 6D-E, control injection vs 10ng
VEGF121b Po0.05 for ischaemic and normal vessel growth). The
overall result was an increase in the proportion of normal
vasculature in these retinae (see Figure 6E). Injection of control
solution had no effect compared with contralateral eye (see
Figure 6B uninjected control vs control injected eye, P40.05,
paired t-test).
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Figure 6 VEGF121b reduces hypoxia-induced retinal neovascularisation after single intraocular injection. The oxygen-induced retinopathy mouse model
leads to neovascularisation induced by hypoxia. (A) Flat mounted mouse retinas with vessels visualised by isolectin staining. Ischaemic and neovascularised
areas are circled (i, ischaemic, n, neovascular and r, normal retinal vessels). Normal retinal vessels (vii) are slender compared to neovascular vessels (viii). (B)
Quantification of neovascularisation, ischaemic and normal vessel growth compared to matched uninjected control eye (paired t-test, *Po0.05, **Po0.01).
(C–E). Distribution of ischaemic, neovascular and normal vessel growth in injected retinas relative to uninjected eye showed that VEGF121b reduced
neovascularisation (C) and the ischaemic areas (D) leading to an increase in the revascularisation (E). (One-way ANOVA, Bonferroni post hoc test,
DPo0.05, DDPo0.01 compared to vehicle injected¼0ng).
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sDISCUSSION
The existence of a second family of VEGF isoforms with overtly
different properties from that of the conventional VEGF species
required a radical re-evaluation of VEGF biology, not only
academically – thousands of manuscripts have attempted to
quantify ‘VEGF’ in body fluids or tissues using primers, probes
or antibodies that would not distinguish these contrasting families;
but also in terms of the pathogenesis of disease and the potential
clinical importance of VEGFxxx/VEGFxxxb balance, because these
families derive from the same gene. VEGF165b is widely expressed
(Bates et al, 2002, 2006; Cui et al, 2004; Perrin et al, 2005;
Pritchard-Jones et al, 2007; Varey et al, 2008) and may form the
pre-dominant isoform in many tissues (Perrin et al, 2005; Varey
et al, 2008). The physiological role of these isoforms is only just
now being elucidated in normal tissues, and it seems that they act
as a brake on excess angiogenesis during conditions of controlled
growth or VEGFxxx expression. Examples include development
of the ovary, where the VEGFxxxb levels are maintained to prevent
angiogenesis into the developing germ bud and so prevent
formation of a testicular artery (VEGFxxxb antibodies are
angiogenic in this model, Artac et al, in press), in the virgin
mammary fat pad, where VEGFxxx levels are prevented from
inducing angiogenesis until lacteal formation, when VEGFxxxb
levels fall (and prevention of this fall results in reduced milk
production) (Qiu et al, 2008), and in the eye where a relative drop
in VEGFxxxb levels is accompanied with angiogenesis in the retina
in diabetes (Perrin et al, 2005). Increased VEGFxxxb levels also
seem to be required for normal pregnancy, as a failure to
upregulate VEGFxxxb in first trimester pregnancies is associated
with subsequent maternal–fetal pathology (Bills et al, 2009).
The development of an angiogenic milieu within a stable and
non-angiogenic tissue, may depend to some degree on changes in
gene (over) transcription or suppression but also on changes in
mRNA splicing control. The control of splicing between the two
VEGF isoform families has begun to be elucidated, and it has been
shown that multiple stimulatory signals can differentially affect the
choice of splice site in the terminal exon, including hypoxia (Varey
et al, 2008), IGF, TNF and PDGF (Nowak et al, 2008), which all
favour proximal splice site selection in exon 8, and hence
angiogenic isoforms, and the latter three growth factors suppress
distal splicing, whereas hypoxia seems not to affect it. TGF-b,o n
the other hand, seems to favour distally spliced isoforms (Nowak
et al, 2008). This seems to be through mechanisms involving splice
factors such as ASF/SF2 and SRp55. Additionally, alteration of
splicing has been seen in human and animal models of disease
including in Denys Drash Syndrome (Schumacher et al, 2007),
kidney, prostate and colon cancer (Bates et al, 2002; Woolard et al,
2004; Varey et al, 2008; Rennel et al, 2008a), malignant melanoma
(Pritchard-Jones et al, 2007) where the PSS is favoured and animal
models of glaucoma where the DSS is favoured (Ergorul et al,
2008). However, there is very little known about regulation of
splice site choice in the terminal exon from the exon 5 splice donor
site, but the earlier studies on hypoxia indicate that this is unlikely
to be a regulatory factor for VEGF121b.
The most studied VEGFxxxb family member – VEGF165b – has
been clearly shown not to be angiogenic. Other researchers have
shown that the six amino acids of exon 8b are required for the anti-
angiogenic activity of VEGF165b because artificially generated
VEGF159 lacking both exons 8a and b, which is not angiogenic
(Cebe Suarez et al, 2006). Exon 8a seems to be required for heparin
and neuropilin-1 binding and full activation of the VEGFR-1 and -2,
as it is likely to interfere with the correct folding and 3D structure of
the protein, resulting in differential activation of VEGFR-2 tyrosine
phosphorylation, and hence downstream signalling (Cebe Suarez
et al, 2006; Cebe-Suarez et al,2 0 0 8 ;K a w a m u r aet al,2 0 0 8 ) .H e r e ,w e
present for the first time new data suggesting that the presence of
exon 8b in a different VEGFxxxb family member endows it with
similar properties to VEGF165b: VEGF121b inhibits experimental
endothelial cell migration in vitro and new vessel formation in vivo
in tumour and non-tumour-related angiogenesis. The VEGFxxxb
family members seem to share similar properties.
We have shown that VEGF121b has similar bio-distribution after
i.v. injection to VEGF165b and a similar proportion of injected bolus
reaching a single implanted tumour – with around 2% for VEGF121b
and 6% for VEGF165b( R e n n e let al, 2008b). Furthermore, we have
shown in this study and in our earlier work (Woolard et al,2 0 0 4 )
that these two VEGFxxxb family members bind the conventional
tyrosine kinase VEGF receptors. VEGF165bd o e sn o tb i n dn e u r o p i -
lin-1 (Kawamura et al, 2008), and there is evidence that VEGF121
also binds neuropilin poorly, suggesting that VEGF121b would not
bind it either. von Wronski et al (2007) have highlighted the
likelihood that neuropilin-1 binds the residues coded for by exon 8a
and replacement by 8b results in VEGF isoforms that do not seem to
show neuropilin-1 binding (Cebe Suarez et al, 2006).
Although we have shown that VEGF165ba n dV E G F 121bb i n dt ot h e
conventional VEGF receptors, further work will be required to
investigate the mechanistic differences between VEGF121b and its
corresponding isoform VEGF121. Studies into the mechanistic
contrast between VEGF165ba n dV E G F 165 are more advanced with
increasing evidence now emerging that VEGF165b, although binding
to VEGFR-2 with equal affinity as VEGF165, is not simply a classical
competitive inhibitor. VEGF165b does stimulate the phosphorylation
of VEGFR-2 but qualitatively in a unique way. Although VEGF165b
does lead to the phosphorylation of tyrosine residues of the VEGF
receptor, tryptic phosphopeptide mapping and the use of phospho-
site-specific antibodies have shown that VEGF165b is considerably
poorer than VEGF165 in inducing phosphorylation of the angiogenic
positive regulatory site Y1052 (Y1054 in human sequence) in
VEGFR-2 (Kawamura et al, 2008). This study also confirmed that the
ability of different VEGF isoforms to induce angiogenesis correlated
with their abilities to bind the VEGF co-receptor neuropilin-1
(Kawamura et al, 2008). Whether or not VEGF121b activates VEGFR-
2 in a similar way is yet to be investigated, as are the potential effects
of simultaneous VEGF121ba n dV E G F 165b administration of receptor
activity, angiogenesis or tumour growth.
Another significant finding here is that VEGF121b seems to act as
a survival factor for human endothelial cells. This activity seems to
be VEGFR dependent, and uses classical survival pathways such as
the PI3 kinase and MEK/ERK pathways. This provides a potential
explanation for the surprising finding that the ischaemic region in
the retinal neovascular preparations was reduced by VEGF121b
administration. This is of particular interest as it suggests a
vascular normalisation in the retina, leading to the possibility that
VEGF121b may be of use in ischaemic retinal diseases associated
with angiogenesis such as diabetic retinopathy.
In summary, we provide new information about the existence,
expression and activity of a second member of the anti-angiogenic
VEGFxxxb family. Our data confirm that VEGF121b has similar
inhibitory properties on the process of in vivo angiogenesis and
the components of angiogenesis in vitro as does VEGF165b,
supporting the notion that the replacement of the terminal six
amino acids with those coded for by exon 8b is of crucial
importance in converting the dominant pro-angiogenic growth
factor into a positively anti-angiogenic molecule that may have
broad therapeutic potential. Further studies will be required to
elucidate its mechanism of action of VEGF121b and its potential
clinical value along with its other family member VEGF165b.
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